EGFR inhibitors sensitize non-small cell lung cancer cells to TRAIL-induced apoptosis

Chinese Journal of Cancer

Volumn 30, Issue 10, 2011, Pages 701-711

  Lin, Tong Yu ^a   Xu, Fei ^a   Tian, Ying ^a   Huang, Yan ^a   Zhang, Ling Ling ^a   Guo, Zheng Zheng ^a   Huang, Jia Jia ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Epidermal growth factor receptor (egfr); Gene therapy; Non small cell lung cancer; Target therapy; Tumor necrosis factor re lated apoptosis in ducing ligand (trail)

Indexed keywords

ADENOVIRUS VECTOR; CETUXIMAB; ERLOTINIB; GEFITINIB; PROTEIN BAX; PROTEIN KINASE B; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GENE THERAPY; CANCER INHIBITION; CELL LEVEL; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PROMOTER REGION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR VOLUME; TUMOR XENOGRAFT; UPREGULATION; VIRAL GENE DELIVERY SYSTEM; VIRUS TITRATION;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SYNERGISM; FEMALE; GENETIC THERAPY; GENETIC VECTORS; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSFECTION; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80054722876     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.011.10107     Document Type: Article

References (34)

1. Brabender J, Danenberg KD, Metzger R, et al. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival [J]. Clin Cancer Res, 2001,7(7):1850-1855.
2. Fontanini G, De Laurentiis M, Vignati S, et al. Evaluation of epidermal growth factor-re lated growth factors and receptors and of neoangiogenesis in completely resected stage I -IIIA non-s mall-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival [J]. Clin Cancer Res, 1998,4(1):241-249.
3. Rusch V, Klimstra D, Venkatraman E, et al. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression [J]. Clin Cancer Res, 1997,3(4):515-522.
4. Ritter CA, Arteaga CL. The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors [J]. Semin Oncol, 2003,30(1 Suppl):3-11.
5. Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non -small-cell lung cancer (FLEX): an open-la bel randomised phase III trial [J]. Lancet, 2009,373(9674):1525-1531.
6. Butts CA, Bodkin D, Middleman EL, et al. Randomized phase II study of gemcitabine plus cisplatin or carboplatin, with or without cetuximab, as first-lin e therapy for patients with advanced or metastatic non small-cell lung cancer [J]. J Clin Oncol, 2007,25(36):5777-5784.
7. Rosell R, Robinet G, Szczesna A, et al. Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-lin e therapy in EGFR-expressing advanced non -small-cell lung cancer [J]. Ann Oncol, 2008,19(2):362-369.
8. Fukuoka M, Yano S, Giaccone G, et al. Multi-in stitutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [J]. J Clin Oncol, 2003,21(12):2237-2246.
9. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non -small cell lung cancer: a randomized trial [J]. JAMA, 2003,290 (16):2149-2158.
10. Niho S, Kubota K, Goto K, et al. First-lin e single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study [J]. J Clin Oncol, 2006,24(1): 64-69.
11. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non -small-cell lung cancer: a phase III trial-INTACT 1 [J]. J Clin Oncol, 2004,22(5):777-784.
12. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non -small-cell lung cancer: a phase III trial-INTACT 2 [J]. J Clin Oncol, 2004,22(5):785-794.
13. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-7 74) combined with carboplatin and paclitaxel chemotherapy in advanced non -small-c ell lung cancer [J]. J Clin Oncol, 2005,23 (25):5892-5899.
14. Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-s mall cell lung cancer: the Tarceva Lung Cancer Investigation trial [J]. J Clin Oncol, 2007,25(12):1545-1552.
15. Suliman A, Lam A, Datta R, et al. Intracellular mechanisms of TRAIL: apoptosis through mitochondrial-d ependent and -in dependent pathways [J]. Oncogene, 2001,20 (17):2122-2133.
16. Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis[J]. Immunity, 1995,3(6):673-682.
17. Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand [J]. J Clin Invest, 1999,104(2):155-162.
18. MacFarlane M. TRAIL-in duced signalling and apoptosis [J]. Toxicol Lett, 2003,139(2-3):89-97.
19. Wang S, El-Deiry WS. TRAIL and apoptosis induction by TNF-family death receptors [J]. Oncogene, 2003,22(53):8628-8633.
20. Lee J, Hampl M, Albert P, et al. Antitumor activity and prolonged expression fromaTRAIL-e xpressing adenoviral vector [J]. Neoplasia, 2002,4(4):312-323.
21. Lin T, Huang X, Gu J, Zhang L, et al. Long-te rm tumor-free survival from treatment with the GFP-TRAIL fusion gene expressed from the hTERT promoter in breast cancer cells [J]. Oncogene, 2002,21(52):8020-8028.
22. Katz MH, Spivack DE, Takimoto S, et al. Gene therapy of pancreatic cancer with green fluorescent protein and tumor necrosis factor-re lated apoptosis-in ducing ligand fusion gene expression driven by a human telomerase reverse transcriptase promoter [J]. Ann Surg Oncol, 2003,10(7):762-772.
23. Voortman J, Resende TP, Abou El Hassan MA, et al. TRAIL therapy in non-s mall cell lung cancer cells: sensitization to death receptor-m ediated apoptosis by proteasome inhibitor bortezomib [J]. Mol Cancer Ther, 2007,6(7):2103-2112.
24. Gibson SB. Epidermal growth factor and trail interactions in epithelial-derived cells [J]. Vitam Horm, 2004,67:207-227.
25. Kagawa S, He C, Gu J, et al. Antitumor activity and bystander effects of the tumor necrosis factor-re lated apoptosis-in ducing ligand (TRAIL) gene [J]. Cancer Res, 2001,61(8):3330-3338.
26. Jo M, Kim TH, Seol DW, et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-re lated apoptosis-inducing ligand [J]. Nat Med, 2000,6(5): 564-567.
27. Coldren CD, Helfrich BA, Witta SE, et al. Baseline gene expression predicts sensitivity to gefitinib in non-s mall cell lung cancer cell lines [J]. Mol Cancer Res, 2006,4(8):521-528.
28. Kim DR, Park MY, Lee CS, et al. Combination of vorinostat and adenovirus-TRAIL exhibitsa synergistic antitumor effect by increasing transduction and transcription of TRAIL in lung cancer cells [J]. Cancer Gene Ther, 2011,18(7):467-477.
29. Gibson EM, Henson ES, Haney N, et al. Epidermal growth factor protects epithelial-derived cells from tumor necrosis factor-re lated apoptosis-in ducing ligand-in duced apoptosis by inhibiting cytochrome c release [J]. Cancer Res, 2002,62(2): 488-496.
30. Ravi R, Bedi A. Requirement of BAX for TRAIL/Apo2L-in duced apoptosis of colorectal cancers: synergism with sulindac-mediated inhibition of Bcl-x (L) [J]. Cancer Res, 2002,62(6): 1583-1587.
31. Park SY, Seol DW. Regulation of Akt by EGF-R inhibitors, a possible mechanism of EGFR-R inhibitor-e nhanced TRAIL-induced apoptosis [J]. Biochem Biophys Res Commun, 2002,295(2):515-518.
32. Aydin C, Sanlioglu AD, Bisgin A, et al. NF-B targeting by way of IKK inhibition sensitizes lung cancer cells to adenovirus delivery of TRAIL [J]. BMC Cancer, 2010,10:584.
33. Kurai J, Chikumi H, Hashimoto K, et al. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines [J]. Clin Cancer Res, 2007,13(5):1552-1561.
34. Van Schaeybroeck S, Kyula J, Kelly DM, et al. Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non-small cell lung cancer cells [J]. Mol Cancer Ther, 2006,5(5): 1154-1165.